Laboratorios Farmaceuticos Rovi revenue and financials
€58.85Change from previous close: +1.20%Absolute change: +€0.70
In the fiscal year ended December 2025, Laboratorios Farmaceuticos Rovi reported revenue of €743.48M (−2.65% year over year). Net income was €140.44M, a net margin of 18.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −2.65%
- 2025 vs 2024
- Net income growth
- +2.60%
- 2025 vs 2024
- Net margin
- 18.9%
- 2024: 17.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 956 | 832 | 800 | 879 | — |
| Current assets | 567 | 490 | 509 | 623 | — |
| Cash and equivalents | 98.0 | 27.2 | 25.3 | 125 | — |
| Short-term investments | — | 0.2 | — | — | — |
| Inventory | 288 | 330 | 338 | 312 | — |
| Net property, plant and equipment | 331 | 287 | 254 | 216 | — |
| Goodwill | 2.7 | 0.0 | — | — | — |
| Other intangible assets | 33.2 | 34.0 | 33.9 | 35.7 | — |
| Long-term investments | 19.2 | 19.5 | 0.6 | 2.2 | — |
| Current liabilities | 181 | 157 | 200 | 294 | — |
| Accounts payable | 81.8 | 86.9 | 108 | 124 | — |
| Long-term debt | 83.9 | 80.5 | 38.6 | 46.0 | — |
| Total debt | 122 | 114 | 65.4 | 72.1 | — |
| Total liabilities | 280 | 250 | 256 | 357 | — |
| Total equity (incl. minority) | 675 | 582 | 543 | 521 | — |
| Retained earnings | 578 | 486 | 556 | 456 | — |
| Minority interest | 11.0 | 9.5 | 4.1 | 1.4 | — |